UFPT · Investment summary · as of 4 August 2026
Priced slightly ahead of what the business has demonstrated
Business type: Compounder · mature and structurally stable
The evidence needed to judge business quality is not established, so the underwriting supports no position.
At $267.53, UFPT requires a 6% five-year revenue growth rate to justify its enterprise value — more than the business has ever demonstrated, at 3%.
The disagreement with the market is about the GROWTH RATE — specifically whether Q2 2026's +12.4% organic is a turn or a quarter. Growth axis −2.58pp, margin axis −2.24pp: both fail, growth by more.
The value rests on an exit multiple of 22.5x, a terminal operating margin of 16% and a 9.6% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: Intuitive Surgical brings production in-house.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | The disagreement with the market is about the GROWTH RATE — specifically whether Q2 2026's +12.4% organic is a turn or a quarter. Growth axis −2.58pp, margin axis −2.24pp: both fail, growth by more. |
| What do we forecast? | Revenue growth of 3% demonstrated; a terminal operating margin of 16%; an exit multiple of 22.5x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is -2.6 percentage points. |
| What is it worth? | Twelve-month target $295.36, +10% from the struck price. Scenario-weighted expected return net of costs +10.4%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| any two consecutive quarterly 8-K/EX-99.1 releases through FY2027 | Organic growth sales rate, UFPT's own Organic Sales Growth Rate… | Neither leg of the condition opposite is met at this date | Organic sales growth below +4.0% in two consecutive quarters |
| each 10-K (FY2026 filed ~Feb 2027) | Customer-concentration disclosure × total revenue | Intuitive Surgical revenue at or above $130m on a trailing-twelve-month basis | Intuitive Surgical revenue below $130m on a trailing-twelve-month basis |
| consecutive 10-Qs | GAAP gross margin | Gross margin at or above 28.0% for two consecutive quarters | Gross margin below 28.0% for two consecutive quarters |
| any quarter | Presence of the reconciliation table in the quarterly 8-K/EX-99.1 | Neither leg of the condition opposite is met at this date | The company ceases to publish the Organic Sales Growth Rate Reconciliation |
Intuitive Surgical brings production in-house. UFPT's own 10-K names it: 'the risk that our two largest customers… will not purchase the expected volume of goods… because… our largest customer decides to manufacture the products itself or through one of its affiliates.' Intuitive was 22.1% of Q1 2026 revenue and 24.3% of FY2025, with FY2025 dollars flat (−0.5%) year on year.
Estimated probability 15%, against the 18% level at which the position would be resized. It sits within that level.
Falsifiable and fundamental — not one of them is a price condition.
Trim or exit when the forward 12-month expected return falls to zero. Concretely: at an unchanged FY2027 GAAP EBIT of ~$107.7m that is EV/EBIT above 23.0x with organic growth still below +8%, or the $295 target reached without two consecutive quarters of organic growth above +8%. On approach to the $295.36 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Not determined | Is the business worth owning under its declared economic type? Not established on the evidence on file. |
| Valuation | Not met | Is the operating path required by today's price achievable? |
| Liquidity | Not determined | Can the intended position be built and exited in the right vehicle? Not established on the evidence on file. |
| Downside | Met | Intuitive Surgical brings production in-house. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The gap between what today's price requires and what the business has demonstrated is -2.6 percentage points, and that gap — not the multiple — is the case that the security is mispriced. The most important unresolved uncertainty is whether this is a business worth owning at all — the evidence for its quality is not established. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $235.36, which forces an immediate review.